This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
The human back is a complex structure with bones, nerves, tendons, discs, and more — all places where something can go wrong and cause pain, which, for many people, becomes a long-term or chronic problem. Life stresses and other medical and mental health conditions aggravate the problem. With so many pieces, it’s hard to get a holistic view of the puzzle or pinpoint the cause of the pain. “People tend to focus on one aspect or another,” said Jeffrey Lotz, Ph.D., a medical engineer who studies back pain at the University of California, San Francisco. “Some people think it’s largely
Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.
Known as the “disease with a thousand faces,” systemic lupus erythematosus is a lifelong autoimmune disease with a wide range of symptoms and signs—fatigue, fever, joint pain, facial rash and skin lesions, shortness of breath, and more. It may develop suddenly or slowly and be mild or severe, with people affected going through periods of flare up and remission of their symptoms.
A research team led by Dr. Makarand Risbud of Thomas Jefferson University tested whether treatment with the drugs dasatinib and quercetin would prevent disc degeneration in mice. Both drugs are senolytics, which selectively remove aged cells known as senescent cells.
Researchers have identified a potential treatment to reduce the risk of cardiovascular disease in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease.
Video of a Facebook Live discussion on lupus research, treatment, and care, moderated by Rev. Cheryl Ward and featuring experts in the field.